These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1478285)

  • 21. Phase III adjuvant studies in operable malignant melanoma (review).
    Lejeune FJ
    Anticancer Res; 1987; 7(4B):701-5. PubMed ID: 3314671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Regional perfusion treatment in primary malignant melanomas of the extremities. (Microstage IV/V according to Clark and tumor thickness over 1.5 mm)].
    Schraffordt Koops H; Oldhoff J
    Hautarzt; 1982 Sep; 33(9):506-10. PubMed ID: 7174325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
    J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results.
    Fraker DL; Alexander HR
    Melanoma Res; 1994 Mar; 4 Suppl 1():27-9. PubMed ID: 8038592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolated regional limb hyperthermic perfusion as treatment for melanoma.
    Loescher LJ; Leigh S
    Cancer Nurs; 1984 Dec; 7(6):461-7. PubMed ID: 6568866
    [No Abstract]   [Full Text] [Related]  

  • 26. Malignant melanoma and isolated limb perfusion.
    Giraud RM
    S Afr J Surg; 1984; 22(4):243-8. PubMed ID: 6523302
    [No Abstract]   [Full Text] [Related]  

  • 27. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
    Lejeune FJ; Eggermont AM
    J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
    [No Abstract]   [Full Text] [Related]  

  • 28. [Regional hyperthermic perfusion--therapeutic concept and long term results].
    Göhl J; Hohenberger W
    Langenbecks Arch Chir Suppl Kongressbd; 1992; ():494-501. PubMed ID: 1493314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [On the morphologic changes in malignant melanomas of the skin during therapy using the method of regional perfusion with chemical preparations].
    Abbasov AT; Parshikova SM
    Arkh Patol; 1966; 28(11):42-5. PubMed ID: 6002050
    [No Abstract]   [Full Text] [Related]  

  • 30. [Extremity perfusion in malignant melanoma].
    Hohenberger W; Meyer T; Göhl J
    Chirurg; 1994 Mar; 65(3):175-85. PubMed ID: 8194401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
    Kettelhack C; Hohenberger P; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three unresolved issues in the surgical treatment of melanoma.
    Boddie AW; Balch CM
    Oncology (Williston Park); 1988 Nov; 2(11):39-44, 48-50. PubMed ID: 3275043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hyperthermic isolation perfusion of the extremities in malignant melanomas and soft tissue sarcomas].
    Tonak J; Hohenberger W; Göhl J
    Chirurg; 1984 Aug; 55(8):499-504. PubMed ID: 6488994
    [No Abstract]   [Full Text] [Related]  

  • 37. Current status of hyperthermic limb perfusion for in-transit melanoma.
    Ross MI
    Int J Hyperthermia; 2008 May; 24(3):205-17. PubMed ID: 18392999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolation perfusion. An adjunct to surgical excision in the primary treatment of melanoma of the extremities.
    Alrich EM; Manwaring JL; Horsley JS
    Am J Surg; 1971 May; 121(5):583-5. PubMed ID: 5557770
    [No Abstract]   [Full Text] [Related]  

  • 39. Improved survival rates of patients with acral lentiginous melanoma treated with hyperthermic isolation perfusion, wide excision, and regional lymphadenectomy.
    Fletcher JR; White CR; Fletcher WS
    Am J Surg; 1986 May; 151(5):593-8. PubMed ID: 3518512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perfusion of melanoma. 105 isolated perfusions in 92 patients.
    Golomb FM
    Oncology; 1972; 26(2):197-205. PubMed ID: 4626136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.